Innovative Medicines Initiative, TO 56, Office 6/4 B-1049 Brussels, Belgium.
Eur J Immunol. 2013 Feb;43(2):298-302. doi: 10.1002/eji.201370024.
The Innovative Medicines Initiative (IMI) was established in 2008 as a public-private partnership between the European Union and the European Federation of Pharmaceutical Industries and Associations with the mission to promote the development of novel therapies through collaborative efforts based on the concept of pre-competitive research. Several consortia supported by IMI are dedicated to immuno-inflammatory disorders, immune-based biopharmaceuticals and vaccines. Herein, we present the key principles underlying IMI, briefly review the status of projects related to translational immunology, and present future topics of interest to immunologists.
创新药物倡议（IMI）成立于 2008 年，是欧盟与欧洲制药工业协会联合会之间的公私合作伙伴关系，其使命是通过基于预竞争研究理念的合作努力，促进新型疗法的开发。IMI 支持的几个联盟致力于免疫炎症性疾病、基于免疫的生物制药和疫苗。本文介绍了 IMI 的基本原则，简要回顾了与转化免疫学相关项目的现状，并提出了免疫学家感兴趣的未来主题。
